US FDA accepts for review the resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria: Paris Monday, November 18, 2024, 11:00 Hrs [IST] The US Food and Drug Admin ...
The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental Biologics License ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback